Tumor development, or tumorigenesis, broadly describes the process by which normal cells gain malignant properties. Tumor development includes growth functions like cellular differentiation, proliferation, and metastasis.
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
The Warburg effect or aerobic glycolysis is a well-known cancer metabolism phenomenon and serves as an established test for tumor detection with FDG-PET scanning technology. Cancer cells swit...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Using the NSGTM mouse (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), JAX In Vivo Pharmacology Services has combined the human CD34+ hematopoietic stem cell engrafted NSGTM (hu-CD34 NSGTM) with human pat...
Surface plasmon resonance (SPR) is a sensitive, label-free technique that detects mass changes due to biomolecular interactions on a surface. This versatile method has been used to evaluate t...
Nanotechnology, the engineering and manufacture of materials at the atomic and molecular scale, is used at BIND Therapeutics to develop novel Accurin™ nanomedicines that utilize cytotoxic age...
The webinar will start at 4am Pacific Time, 7am Eastern Time, 1pm Central European Summer Time, 7pm China Standard Time
Extracellular vesicles (EVs) including exosome and microvesi...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
Date: Wednesday, June 24th, 2015 Time: 09:00AM PDT, 12:00PM EDT, 4:00PM GMT Solaris™ is a new open-air fluorescence imaging system developed by PerkinElmer, enabling translational in vivo pre...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Asthma is heritable, influenced by the environment, and is modified by in utero exposures and aging; all of these features are also common to epigenetic regulation. Furthermore, genetic varia...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released t...
Drug developers are rapidly adopting three-dimensional (3D) cell cultures for drug screening since they provide a more physiologically relevant environment than two-dimensional cell cultures ...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
The Warburg effect or aerobic glycolysis is a well-known cancer metabolism phenomenon and serves as an established test for tumor detection with FDG-PET scanning technology. Cancer cells swit...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Using the NSGTM mouse (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), JAX In Vivo Pharmacology Services has combined the human CD34+ hematopoietic stem cell engrafted NSGTM (hu-CD34 NSGTM) with human pat...
Surface plasmon resonance (SPR) is a sensitive, label-free technique that detects mass changes due to biomolecular interactions on a surface. This versatile method has been used to evaluate t...
Nanotechnology, the engineering and manufacture of materials at the atomic and molecular scale, is used at BIND Therapeutics to develop novel Accurin™ nanomedicines that utilize cytotoxic age...
The webinar will start at 4am Pacific Time, 7am Eastern Time, 1pm Central European Summer Time, 7pm China Standard Time
Extracellular vesicles (EVs) including exosome and microvesi...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
Date: Wednesday, June 24th, 2015 Time: 09:00AM PDT, 12:00PM EDT, 4:00PM GMT Solaris™ is a new open-air fluorescence imaging system developed by PerkinElmer, enabling translational in vivo pre...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Asthma is heritable, influenced by the environment, and is modified by in utero exposures and aging; all of these features are also common to epigenetic regulation. Furthermore, genetic varia...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released t...
Drug developers are rapidly adopting three-dimensional (3D) cell cultures for drug screening since they provide a more physiologically relevant environment than two-dimensional cell cultures ...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
